342897-54-5

Basic information

• Product Name: 4-Benzoxazolamine,2-methyl-(9CI)
• Synonyms: 4-Benzoxazolamine,2-methyl-(9CI);2-Methyl-benzooxazol-4-ylaMine;2-methylbenzo[d]oxazol-4-amine
• CAS NO: 342897-54-5
• Molecular Formula: C₈H₈N₂O
• Molecular Weight: 148.164
• Product Categories: AMINEPRIMARY
• Mol File: 342897-54-5.mol

Chemical Properties

• Boiling Point: 290.643°C at 760 mmHg
• Flash Point: 129.577°C
• Appearance: /
• Density: 1.254g/cm³
• Vapor Pressure: 0.002mmHg at 25°C
• Refractive Index: 1.659
• CAS DataBase Reference: 4-Benzoxazolamine,2-methyl-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Benzoxazolamine,2-methyl-(9CI)(342897-54-5)
• EPA Substance Registry System: 4-Benzoxazolamine,2-methyl-(9CI)(342897-54-5)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 342897-54-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-Benzoxazolamine,2-methyl-(9CI) is used as a key intermediate in the synthesis of various medications due to its unique chemical structure and reactivity. Its potential therapeutic properties make it a valuable compound in the development of new drugs for the treatment of different medical conditions.
Used in Research Applications:
In the field of research, 4-Benzoxazolamine,2-methyl-(9CI) serves as a versatile compound for studying organic chemistry reactions and exploring its potential applications in the synthesis of organic compounds. Its unique structure and reactivity make it an interesting subject for scientific investigations and the development of novel chemical processes.

InChI:InChI=1/C8H8N2O/c1-5-10-8-6(9)3-2-4-7(8)11-5/h2-4H,9H2,1H3

Upstream product

• 478553-83-2 2-methyl-4-nitrobenzo[d]oxazole 
• 59820-29-0 2-acetylamino 3-nitro phenol 
• 69194-51-0 1-acetoxy-2-acetylamino-3-nitro-benzene 
• 7439-89-6 iron 
• 603-85-0 2-Amino-3-nitrophenol 

Relevant articles and documents

ALPHA, BETA-UNSATURATED AMIDE COMPOUND

An object of the present invention is to provide an α,β-unsaturated amide compound or a pharmaceutically acceptable salt or the like thereof having anticancer activity and the like. The α,β-unsaturated amide compound represented by the following formula (I) or a pharmaceutically acceptable salt or the like thereof has anticancer activity and the like: [wherein, "A" represents optionally substituted heterocyclic diyl, R1 represents hydrogen atom or optionally substituted lower alkyl, R2 represents optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted aliphatic heterocyclic group or optionally substituted aromatic heterocyclic group, X represents -O-, -S-, -SO2-, -NRX1- (wherein, RX1 represents hydrogen atom or lower alkyl), -CHRX2- (wherein, RX2 represents hydrogen atom or hydroxy), -CH=CH-, -CO- or -NH-CO-, and n1 and n2 are the same or different, and each represents 0 or 1].

CONDENSED HETEROCYCLIC COMPOUND

A compound represented by the general formula (I) [R1 represents a C1-6 alkyl group, a halogen atom, or the like; A represents a phenylene group, or the like; X represents —CH(R3)—, —O—, —NH—, or the like; Y represents —O—, —NH—, —N═, or —S—; . . . represents a single bond or double bond; n represents 1 to 3; R2 represents a C1-6 alkyl group, a C1-6 alkoxy group, or the like; and R3 represents hydrogen atom, a C1-6 alkyl group, or the like], or a salt thereof which has a blood LDL cholesterol-reducing action, and is useful as an active ingredient of medicaments.

Design and Synthesis of 2-Methyl-7-aminobenzoxazole as Auxiliary in the Palladium(II)-Catalyzed Arylation of a beta-Positioned C(sp3)-H Bond

A palladium(II)-catalyzed direct arylation of methylene C(sp3)-H bonds by 2-methyl-7-aminobenzoxazole as an effective auxiliary is reported. This process exhibited high beta-site selectivity, broad substrate scope, and compatibility with different functional groups with moderate to high yields up to 89%.

METHOD FOR THE PREPARATION OF FUSED HETEROCYCLIC SUCCINIMIDE COMPOUNDS AND ANALOGS THEREOF

Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.

Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function

Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.

Synthesis and Reaction of 5,6,7,8-Tetrahydro-4H-oxazolo[4,5-c]azepin-4-ones

The synthesis of 5,6,7,8-tetrahydro-4H-oxazolo[4,5-c]azepin-4-ones 5a,b and 1,3-benzoxazol-4-amines 4a,b are described starting from 4,5,6,7-tetrahydro-1,3-benzoxazol-4-ones. Thionation of 5a,b followed by alkylation with ethyl bromoacetate led to the cor